Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | January 31, 2022 | January 31, 2022 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | July 06, 2026 | July 08, 2026 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | Director | October 04, 2019 | October 05, 2019 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 19, 2025 | May 19, 2025 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date January 31, 2022 · Filed January 31, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.19 · Expires 2032-01-30 | Direct | 85,000 |
Reported balance
After 2022-01-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-31 · Grant · Acquired 85,000 · Balance 85,000 F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and will vest as to 100% of the underlying shares on the first anniversary of the date of grant (January 31, 2023), subject to the director's continued service with the Company.
Enliven Therapeutics, Inc.
Report date July 06, 2026 · Filed July 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,884 |
Ending reported balance
After 2026-07-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-06 · Sale · Disposed 4,111 · Balance 47,773 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F2: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-07-06 · Sale · Disposed 5,889 · Balance 41,884 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026 F3: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2026
F2: This transaction was executed in multiple trades at prices ranging from $49.40 to $50.395. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $50.4306 to $51.3752. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 7,500 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 7,500 · Balance 7,500 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Nurix Therapeutics, Inc.
Report date May 19, 2025 · Filed May 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2035-05-18 | Direct | 25,000 |
Reported balance
After 2025-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-19 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 19, 2026, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Oric Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.17 · Expires 2036-01-01 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 27,344 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.65 · Expires 2024-06-18 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 49,687 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.91 · Expires 2025-07-27 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 4,716 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.58 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 11,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $180.98 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 8,750 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2018 Filed Oct 3, 2018 21:05 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 5,000 | $3.65 | $18,240.00 |
DisclosureSEC source: 0001567619-18-003657 · doc1.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:48 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.98 | $0.00 |
DisclosureSEC source: 0001209191-18-039411 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 monthly installments following the date of grant. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 4 | $177.79 | $711.16 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 9 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 5,601 | $177.12 | $992,058.64 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 8 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4 F5 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F1 · shares: Represents the aggregate of sales effected on the same day at different prices F7 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $176.68 to $177.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,235 | $175.64 | $216,919.60 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 7 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,605 F5 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F1 · shares: Represents the aggregate of sales effected on the same day at different prices F6 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $175.36 to $176.10 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,953 | $0.00 Strike: $24.18 | $0.00 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · derivative · entry 12 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,859 Underlying: Common Stock · 1,953 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,096 | $0.00 Strike: $20.91 | $0.00 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · derivative · entry 11 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,716 Underlying: Common Stock · 3,096 shares Expires 2025-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 27,343 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · derivative · entry 10 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,344 Underlying: Common Stock · 27,343 shares Expires 2024-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option is fully vested and is immediately exercisable. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,541 | $182.35 | $280,996.26 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 6 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 F1 · shares: Represents the aggregate of sales effected on the same day at different prices F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $182.31 to $182.83 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,411 | $181.48 | $437,544.18 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 5 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,381 F1 · shares: Represents the aggregate of sales effected on the same day at different prices F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $181.01 to $181.92 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 28,440 | $180.28 | $5,127,023.84 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 4 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,792 F1 · shares: Represents the aggregate of sales effected on the same day at different prices F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $180.00 to $180.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,953 | $24.18 | $47,223.54 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,232 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 3,096 | $20.91 | $64,737.36 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 21:00 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 27,343 | $3.65 | $99,747.26 |
DisclosureSEC source: 0001140361-18-028996 · doc1.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 21:05 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantDirector Stock Option (right to buy) · Derivative | 8,750 | $0.00 Strike: $180.98 | $0.00 |
DisclosureSEC source: 0001140361-18-028643 · doc1.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 8,750 shares Expires 2028-06-12 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $133.60 | $13,360.00 |
DisclosureSEC source: 0001140361-18-019388 · doc1.xml · nonDerivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 4,000 | $132.81 | $531,238.80 |
DisclosureSEC source: 0001140361-18-019388 · doc1.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,940 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.55 to $133.36 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 20:30 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 900 | $131.98 | $118,779.48 |
DisclosureSEC source: 0001140361-18-019388 · doc1.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,940 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.22 to $132.21 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:47 UTC | CURIS INC CRIS · Entity 8401 | GrantCommon stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005152 · doc4.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:03 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 400 | $86.28 | $34,511.00 |
DisclosureSEC source: 0001140361-17-041152 · doc1.xml · nonDerivative · entry 3 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $85.88 to $86.58 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:03 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 2,800 | $85.21 | $238,590.52 |
DisclosureSEC source: 0001140361-17-041152 · doc1.xml · nonDerivative · entry 2 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,240 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $84.76 to $85.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 22:03 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,800 | $84.15 | $151,468.92 |
DisclosureSEC source: 0001140361-17-041152 · doc1.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,040 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $83.74 to $84.69 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 22:35 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 10,000 | $75.17 | $751,731.00 |
DisclosureSEC source: 0001140361-17-033124 · doc1.xml · nonDerivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,840 F1 · kind: The transaction reported on this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on June 20, 2017. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $75.00 to $75.365 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 22, 2017 Filed Jun 23, 2017 21:22 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantDirector Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $78.58 | $0.00 |
DisclosureSEC source: 0001140361-17-026014 · doc1.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 01:05 UTC | Forte Biosciences, Inc. TOCA · Entity 9529 | GrantStock Option (right to buy) · Derivative | 4,528 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-17-026754 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,528 Underlying: Common Stock · 4,528 shares Expires 2027-04-11 F1 · derivative.exercise_date: 1/4th of the shares vest one year after 4/1/2017; the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of 4/1/2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:53 UTC | CURIS INC CRIS · Entity 8401 | GrantNon-qualified stock option · Derivative | 120,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-17-016727 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company. Read SEC document |
| November 11, 2016 Filed Nov 14, 2016 20:54 UTC | CURIS INC CRIS · Entity 8401 | GrantNon-qualified stock option · Derivative | 25,000 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0001209191-16-149709 · doc4.xml · derivative · entry 1 Kunkel Lori Anne · CIK 0001536368 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-11-10 F1 · derivative.exercise_date: Options granted under the 2010 Stock Incentive Plan and will vest over a period of four years with 25% of the stock options vesting on November 11, 2017, and an additional 6.25% of the shares during each successive three-month period thereafter until the options are fully vested on November 11, 2020, subject to continued service on the Company's Board. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.